Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Moderna

Q&A: The new COVID vaccine booster is coming. Should you get it?

The COVID-19 vaccine is getting an upgrade.

Tribune News Service

What Are Whales Doing With Moderna

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Moderna Sues Pfizer/BioNTech for Patent Infringement over COVID Vaccine

Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic. Pfizer shares fell nearly 1%, while BioNTech US-listed shares were down about 1.5%…

Asharq Al-Awsat

From analysis to the latest developments in health,
read the most diverse news in one place.

US Covid vaccine maker Moderna suing rivals Pfizer and BioNTech over jab

The company said it believes its rivals’ vaccine infringes on patents Moderna filed between 2010 and 2016

Wales Online

Pfizer asks EU drug regulator to OK tweaked COVID vaccine

Pharmaceuticals Pfizer and BioNTech say they have asked the European Medicines Agency to authorize their updated coronavirus booster vaccine that includes the most recent omicron subvariants

The Independent UK

Moderna sues Pfizer over COVID-19 vaccine patents

The vaccine maker alleges that its rivals Pfizer and BioNTech used some patented features of its mRNA technology to develop their COVID vaccines.

WEKU

Moderna sues Pfizer and BioNTech over Covid-19 vaccine

The vaccine maker said it had filed patent infringement lawsuits in the US and Germany.

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Moderna sues Pfizer/BioNTech alleging patent infringement over Covid vaccine

Moderna seeks unspecified damages in lawsuit over rivals’ jab

Evening Standard

Covid infections at lowest level in two months- ONS

High levels of coronavirus antibodies among the population means the rate of serious illness remains low

Evening Standard

Moderna sues Pfizer, BioNTech over COVID vaccine technology

Moderna Inc. sued Pfizer Inc. and BioNTech SE, claiming the technology in their COVID-19 shot infringes on its patents, a move that sets the stage for a massive legal clash between the vaccine titans.

Tribune News Service

Moderna sues Pfizer over Covid vaccine

Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first Covid-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.

Bangkok Post

Moderna sues Pfizer over patents behind COVID-19 vaccine

COVID-19 vaccine maker Moderna is suing its main competitors Pfizer and the German drugmaker BioNTech, accusing the rivals of copying Moderna’s technology in order to make their own vaccine

The Independent UK

Moderna sues Pfizer-BioNTech accusing them of copying Covid shot technology

‘We believe that Pfizer and BioNTech unlawfully copied Moderna’s inventions, and they have continued to use them without permission,’ Moderna legal officer says

The Independent UK

Moderna sues Pfizer, BioNTech over COVID-19 vaccine

The lawsuit seeks unspecified monetary damages for patent infringement.

Axios

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Tweaked COVID boosters close but how much will they help?

COVID-19 vaccines tweaked to better match today’s omicron threat are expected to roll out in a few weeks but how much will they help

Benzinga

Moderna Whale Trades For August 23

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 53 strange trades.

Tribune News Service

Pfizer files application for booster against latest variants

Pfizer Inc. and BioNTech SE asked the U.S. to authorize a new COVID-19 booster shot customized against the currently circulating COVID-19 variants as governments race to protect their populations against the ever-mutating virus.

Wales Online

Everything you need to know about the new Covid vaccine that targets omicron variant

o serious safety concerns have been identified for this new bivalent treatment

Get all your
news in one place.

100's of premium titles.
One news app.

Daily Mirror

All over-50s to get a new Covid jab targeted to protect against Omicron variant

Britain became the first country to approve a “bivalent” jab on Monday that directly targets Omicron and the original Covid-19 strain - as 29 million people will initially be invited for the vaccine

The Independent UK

‘No second-rate vaccines’ health chief insists as half will miss out on dual-strain booster

Roughly 29 million people are eligible for an autumn booster but there are just 13 million doses of the new bivalent Moderna jab available

Daily Record

Who can get Covid booster as new Omicron jab that targets Omicron to be used

The new jab is bivalent, meaning it protects against the original Covid strain as well as the Omicron variant

WEKU

The U.K. approved omicron-specific booster shots. They're coming to the U.S. soon

In the U.S., officials have asked vaccine makers to target BA.5, rather than the original omicron strain. That has delayed the boosters' development — but officials hope they will be more effective.

Wales Online

Full details of next Covid booster rollout -and Omicron jab will be used

The Government has confirmed who will get another Covid injection and says new vaccine will be used

Pedestrian.tv

The UK Approved A Combo Vaccine To Protect Against Omicron Variants Pls Givvus That One Next

Moderna's bivalent vaccine is seen as the "next step" in COVID protection.

Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

1 … 18 19 20 21

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

European Medicines Agency

76 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.